Extract to table
Pull the structured facts out of a document: parties, dates, amounts, obligations.
Extract to table / fin-48-reserve-analysis-memo.docx
fin-48-reserve-analysis-memo.docx
Parties
Penterra Pharmaceuticals Corp
Harkness LLP
Associates LLP
PPC Corp
Overview Penterra Pharmaceuticals Corp
Penterra Manufacturing Ireland Ltd
Whitmore Valuation Group LLC
Global Intangible Low-Taxed Inc
Dates
September 22, 2022
May 16, 2022
March 15, 2012
July 1, 2012
December 31, 2020
June 2, 2022
June 8, 2022
June 20, 2022
January 1, 2018
Amounts
$62.4
$6.82
$1.47
$312
€47.2
$814.6
$624.1
$278
$361
$852
Obligations
If the recognition threshold is met in Step 1, the entity must then measure the amount of tax benefit to be recognized in its financial statements
Tax positions that fail the more-likely-than-not recognition threshold in Step 1 must be fully reserved (i
Furthermore, under ASC 740-10, the entity must presume that the position will be examined by a taxing authority with full knowledge of all relevant information
The tax impact of any proposed adjustment must be computed using the applicable federal corporate income tax rate for each examination year
The measurement must account for the interrelationship between the CSA and royalty positions, including the potential for correlative adjustments under Treasury Regulation § 1
However, the risk that the IRS will use the PCT undervaluation theory to support adjustments to the ongoing CSA cost-sharing ratios and royalty rates for the examination years is real and must be accounted for